Cambridge Epigenetix Launches Innovative TrueMethyl™ Kits
Cambridge Epigenetix Ltd., a spin out biosciences company, has announced the launch of its TrueMethyl™ kits. The kits represent a ground-breaking development for the epigenetics industry
TrueMethyl™ brings unprecedented clarity to the analysis of DNA by providing quantitative, accurate and repeatable single-base resolution sequencing of the modified bases hydroxymethylcytosine (5-hmC) and methylcytosine (5-mC) for the first time. Early studies indicate that these modifications may have distinct and important physiological functions.
Traditional bisulfite sequencing cannot discriminate between 5-hmC and 5-mC. Recent studies have shown that at some sites in the genome the level of 5-hmC can be comparable to the level of 5-mC, emphasizing the importance of identifying these variants accurately. The high quality and easy to use TrueMethyl™ kits utilize innovative oxidative bisulfite sequencing (oxBS-Seq), a chemistry-based technology invented by Prof. Shankar Balasubramanian and Michael Booth from the University of Cambridge.
TrueMethyl™ kits can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays. Trials of the kits conducted at leading research centers around the world have already begun to yield new insights into genome function and highlighted the advantages of TrueMethyl relative to traditional approaches.
Prof. Wolf Reik, group leader at the The Babraham Institute and the senior author of the recently published Cell Stem Cell paper which is the first published study using TrueMethyl™ said, “Employing chemical oxidation gives very high conversion efficiencies and minimises sequence context effects, giving results of unparalleled quality. Consequently, this pioneering analytical method opens new avenues for basic research, pharmaceutical discovery and diagnostics. This technology was pivotal in enabling us to accurately profile 5-hmC and 5-mC during demethylation of DNA.”